Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent

被引:122
作者
Evans, D. Gareth R. [1 ,4 ,5 ,7 ]
Lalloo, Fiona [7 ]
Ashcroft, Linda [3 ]
Shenton, Andrew [7 ]
Clancy, Tara [7 ]
Baildam, Andrew D.
Brain, Anne [6 ]
Hopwood, Penelope [2 ]
Howell, Anthony [3 ,4 ,5 ]
机构
[1] Univ Manchester, St Marys Hosp, Med Genet Res Grp,Univ Dept Med Genet, Manchester Acad Hlth Sci Ctr,Cent Manchester Fdn, Manchester M13 0JH, Lancs, England
[2] Christie NHS Trust, Dept Psychooncol, Manchester, Lancs, England
[3] Christie NHS Trust, Canc Res UK Med Oncol, Manchester, Lancs, England
[4] Univ Hosp S Manchester NHS Trust, Genesis Prevent Ctr, Manchester, Lancs, England
[5] Univ Hosp S Manchester NHS Trust, Dept Surg, Manchester, Lancs, England
[6] Univ Hosp S Manchester NHS Trust, Dept Plast Surg, Manchester, Lancs, England
[7] Univ Manchester, St Marys Hosp, Reg Genet Serv, Manchester Acad Hlth Sci Ctr,Cent Manchester Fdn, Manchester M13 0JH, Lancs, England
关键词
BILATERAL PROPHYLACTIC MASTECTOMY; BRCA2 MUTATION CARRIERS; HEREDITARY BREAST; FAMILY-HISTORY; SURGICAL DECISIONS; IMPACT; SURVEILLANCE; OOPHORECTOMY; PREDICTORS; MANAGEMENT;
D O I
10.1158/1055-9965.EPI-09-0171
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: The uptake of risk-reducing surgery in women at increased risk of breast and ovarian cancer is highly variable between countries and centers within countries. We have investigated the rate, timing, and age of uptake of surgery in the northwest of England to report the results after up to 7 years in a Regional Genetics center. Methods: Uptake was documented in 211 known unaffected BRCA1/2 mutation carriers from 509 families and in 3,515 women at >25% lifetime risk of breast cancer without known mutations. Results: Of the 211 mutation carriers, 40% opted for bilateral risk-reducing mastectomy (BRRM) and 45% underwent bilateral risk-reducing salpingo-oophorectomy (BRRSPO). Uptake of BRRM was significantly related to lifetime risk and age but continued over several years. In women not known to carry a BRCA mutation, 6.4% of women at 40% to 45% lifetime risk, 2.5% of women at 33% to 39% lifetime risk, and 1.8% of women at 25% to 32% lifetime risk underwent BRRM (P < 0.005). BRRSPO uptake was greater in BRCA1 (52%) than BRCA2 (28%) carriers but in both groups tended to occur within the first 2 years after gene test (except in the youngest age group) and in women between the ages of 35 and 45. Conclusion: To truly assess the uptake of risk-reducing surgery, longer-term follow-up is necessary particularly in younger women who are likely to delay BRRSPO. Careful risk counseling does seem to influence women's decisions for surgery, although the effect is not immediate. (Cancer Epidemiol Biomarkers Prev 2009;18(8): 2318-24)
引用
收藏
页码:2318 / 2324
页数:7
相关论文
共 39 条
[1]
Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme [J].
Amir, E ;
Evans, DG ;
Shenton, A ;
Lalloo, F ;
Moran, A ;
Boggis, C ;
Wilson, M ;
Howell, A .
JOURNAL OF MEDICAL GENETICS, 2003, 40 (11) :807-814
[2]
Genetic testing for a BRCA1 mutation:: Prophylactic surgery and screening behavior in women 2 years post testing [J].
Botkin, JR ;
Smith, KR ;
Croyle, RT ;
Baty, BJ ;
Wylie, JE ;
Dutson, D ;
Chan, A ;
Hamann, HA ;
Lerman, C ;
McDonald, J ;
Venne, V ;
Ward, JH ;
Lyon, E .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2003, 118A (03) :201-209
[3]
Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer [J].
Byrd, Louise M. ;
Shenton, Andrew ;
Maher, Eamonn R. ;
Woodward, Emma ;
Belk, Rachel ;
Lim, Caron ;
Lalloo, Fiona ;
Howell, Anthony ;
Jayson, Gordon C. ;
Evans, Gareth D. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (06) :1535-1542
[4]
Risk reducing mastectomy: outcomes in 10 European centres [J].
Evans, D. G. R. ;
Baildam, A. D. ;
Anderson, E. ;
Brain, A. ;
Shenton, A. ;
Vasen, H. F. A. ;
Eccles, D. ;
Lucassen, A. ;
Pichert, G. ;
Hamed, H. ;
Moller, P. ;
Maehle, L. ;
Morrison, P. J. ;
Stoppat-Lyonnet, D. ;
Gregory, H. ;
Smyth, E. ;
Niederacher, D. ;
Nestle-Kraemling, C. ;
Campbell, J. ;
Hopwood, P. ;
Lalloo, F. ;
Howell, A. .
JOURNAL OF MEDICAL GENETICS, 2009, 46 (04) :254-258
[5]
Evans DG, 2002, J NATL CANCER I, V94, P307, DOI 10.1093/jnci/94.4.307
[6]
EVANS DG, 2008, J MED GENET
[7]
Surgical decisions made by 158 women with hereditary breast cancer aged &lt;50 years [J].
Evans, DGR ;
Lalloo, F ;
Hopwood, P ;
Maurice, A ;
Baildam, A ;
Brain, A ;
Barr, L ;
Howell, A .
EJSO, 2005, 31 (10) :1112-1118
[8]
Risk assessment and management of high risk familial breast cancer [J].
Evans, DGR ;
Lalloo, F .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (12) :865-871
[9]
Uptake of screening and prevention in women at very high risk of breast cancer [J].
Evans, DGR ;
Lalloo, F ;
Shenton, A ;
Boggis, C ;
Howell, A .
LANCET, 2001, 358 (9285) :889-890
[10]
Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up [J].
Foster, C. ;
Watson, M. ;
Eeles, R. ;
Eccles, D. ;
Ashley, S. ;
Davidson, R. ;
Mackay, J. ;
Morrison, P. J. ;
Hopwood, P. ;
Evans, D. G. R. .
BRITISH JOURNAL OF CANCER, 2007, 96 (05) :718-724